Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Exemestane Leads May Rises In UK

Pricewatch UK – May 2020

Executive Summary

Exemestane led the steepest price rises for generics seen in the UK in May. However, concession pricing for the breast cancer drug overestimated the actual prices in the market recorded by WaveData.

You may also be interested in...



Moxonidine Rises Ramp Up In August

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.

UK Aspirin Prices Double In June

Aspirin led the generics with the fastest-rising UK prices in June, according to the latest figures from WaveData.

UK Paracetamol Prices Treble Amid Coronavirus Demand

Average UK trade prices for paracetamol more than trebled in March as the coronavirus outbreak took hold, while the antiviral valaciclovir saw an average increase of over 300%.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel